Approximately 6,000 participants 5 years of age and older will be enrolled in Lyme disease-endemic regions in Europe and the U.S. NEW YORK & SAINT-HERBLAIN, FRANCE– Pfizer Inc. (NYSE: PFE) and Valneva… Read More
Phase 1 Tarlatamab Study Showed Encouraging Antitumor Activity With Median Duration of Response of 13 Months in Small Cell Lung Cancer No Approved Treatment Options Available to Patients in Third-line Setting… Read More
Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential to address… Read More
Collaboration to accelerate the development and access of oncology medicines for cancer patients in China Clinical trial programs combining two of Sanofi’s prioritized oncology assets with sintilimab, the leading… Read More
Using 3D bioprinting to revolutionize tissue testing VoxCell aims to provide a new platform for oncology drug screening. Their tissues are designed to mimic human-like cancer tissues that are used during… Read More
